113 results about "Anti hiv 1" patented technology

The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+ / -0.3): (1+ / -0.3): (3.5+ / -0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and / or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and / or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.

This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.

The invention discloses a pinecone extractive of Yunnan Pinus and a preparation method and medicinal application thereof, and relates to a preparation method of a pinecone extractive of Pinus armandi, pinus yunnanensis, Himalayan pine and / or pinus khasys of Yunnan Pinus and medicinal application thereof. The pinecone extractive of Yunnan Pinus is prepared by the following steps of: soaking crushed pinecones by an alcohol solution, extracting with hot water and then carrying out alcohol-precipitation extracting by a filtrate extracted by water containing soda at room temperature. The pinecone extractive of Yunnan Pinus can effectively restrain AIDS viruses (HIV) and can be expected to be developed into a drug for preventing and controlling aids. The results of pharmacodynamics tests show that the pinecone extractive of Yunnan Pinus has the in vitro anti-HIV-1 activity, and the therapeutic index of the pinecone extractive is larger than 50 (59.99 to 515.48).

The invention belongs to the medicine field and relates to the application of a bromine structural protein BET inhibitor to anti-HIV-1 latency treatment. Experiments prove that the chemical has an HIV-1 latent cell activation induction effect without causing activation of T cells of the whole body, can achieve synergetic activation after being combined with a protein kinase c agonist or cytokines, and can kill activated latent infected cells after being combined with antiretroviral drugs, so as to accelerate the elimination of a latent virus storage. Furthermore, the bromine structural domain protein inhibitor can be used for preparing anti-HIV-1 latency drugs and can provide a new interventional way and strategy for complete cure of AIDS.

The invention provides a method for preparing dibenzocyclooctadiene lignan as shown in formula (I) and an application of the dibenzocyclooctadiene lignan on anti-HIV-1. The method has readily available raw materials, and simple and easy operation, and the prepared compound has remarkable anti-HIV-1 activity. R1=OH, R2=OCH3 or R1=OCH3.

This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.

The invention discloses application of emodin derivatives 3-acetic emodin and 1,8-dihexanoyl emodin in preparation of anti-HIV-1 medicine, and belongs to the field of anti-virus medicines. 3-acetic emodin and 1,8-dihexanoyl emodin are prepared by means of chemical synthesis, the effect of inhibiting replication of HIV-1 viruses in vitro of 3-acetic emodin and 1,8-dihexanoyl emodin is discovered, the number of virus inclusion bodies in infected human macrophages is remarkably reduced, and the 3-acetic emodin and 1,8-dihexanoyl emodin do not have toxic or side effect on the human macrophages. Along with the increasing concentration of the 3-acetic emodin and 1,8-dihexanoyl emodin, the inhibition effect of the 3-acetic emodin and 1,8-dihexanoyl emodin on replication of HIV-1 in vitro is enhanced, expression of Gag genes and p24 protein is gradually reduced; meanwhile, the longer drugs acts, the more remarkable the effect of inhibiting HIV-1 infection is; and the 3-acetic emodin and 1,8-dihexanoyl emodin can be used for preparing anti-HIV-1 medicines.

The invention provides a walnut shell extract and anti-HIV pharmaceutical application thereof, in particular to relating to an extraction and separation method of effective parts of a walnut shell and medical application thereof. The walnut shell extract is prepared by soaking the crushed walnut shell with alkaline solution, extracting, performing alcohol precipitation, recovering a solvent and drying. The obtained walnut shell extract can effectively inhibit HIV (human immunodeficiency virus) and is expected to be developed into a drug for preventing and treating AIDS (acquired immure deficiency syndrome). Pharmacodynamics test results show that the walnut shell has in vitro anti-HIV-1 activity, and therapeutic index thereof is more than 400.

A complex comprising a starch and an active anti-HIV-1 or anti-HIV-2 ingredient of pomegranate juice that is adsorbed on the starch when the starch is in a water insoluble form. The complex inhibits HIV-1 or HIV-2 infection and blocks the binding of HIV-1 or HIV-2 to the CD4 receptor and the CCR5 and CXCR4 coreceptors. The complex is used in a method of preventing HIV-1 or HIV-2 infection comprising administering to a mucous membrane of a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of the complex.

The invention relates to a novel substituted benzoyl urea compound and a preparation method and application thereof. The compound has the structure general formula disclosed in (I), wherein definitions of R1, R2, and R3 are described in the specification, and the compound can be used as a micromolecule inhibitor of Cyclophilin A (CypA); the CypA is a protein with the activity of Peptidyl-prolyl cis-trans isomerase (PPIase), and is related to the in vivo protein folding, assembly and transfer. The current research shows that the CrpA takes part in various physiology approaches, such as autoimmunity depression, HIV-1 invasion infection and the like. Therefore, the compound of the invention can become a novel immunosuppressive drug or anti-HIV-1 drug.

The invention provides an AIDS (HIV-1 / 2) saliva rapid detection reagent, which is to fix a purified recombinant HIV-1 / 2 antigen on a fibrous membrane by adopting a principle of double antigen sandwich method. When the reagent is used, saliva to be detected is added. If a sample contains anti HIV-1 / 2 specific antibody, the antibody is combined with a corresponding antigen on the surface of the membrane to form a composite material. The composite material is captured by an antihuman-IgG monoclonal antibody to form a sandwich substance of the Au-HIVAg-HIV antibody-antihuman-IgG monoclonal antibody, and a purple strip is shown up. A negative sample cannot form the sandwich substance. The AIDS (HIV-1 / 2) saliva rapid detection reagent has high sensibility, better specificity and stability, has convenient operation without an instrument, and can detect AIDS virus in time by single portion. Detection processes can be reduced into one step and can be completed within 5 minutes, and the reagent can be applied to hospitals, epidemic stations and the Entry-Exit Inspection and Quarantine Bureau for field disease diagnose, and home self detection. The reagent uses saliva for directly detecting AIDS to avoid cross infection of blood and completely overcome the defect of laboratory detection technology, can carry out detection without a wound, has high speed, convenience and safety, and fills up domestic blank.

The invention belongs to natural products separating and extracting technical field, particularly relating to a process for simultaneously extracting essential oil, flavone and triterpene out of wrinkled giant hyssop. The invention provides a novel separating and extracting process, which can simultaneously separate and extract essential oil, flavone and triterpene by taking wrinkled giant hyssop as raw materials; the used raw materials can be wrinkled giant hyssop as well as cablin pacholi, fresh or dried herbs as well as fresh or dried leaves, stems or other parts. When fresh wrinkled giant hyssop leaves are used as the raw materials, the essential oil thereof comprises more than 40 volatile components such as cis form - isomenthone, anti form - isomenthone piperitone, hexenoic aldehyde, delta-cadinene, cadinol, alpha-muurolene, limonene and pulegone, wherein main volatile components are the cis form - isomenthone and the anti form- isomenthone, contents of which are 34.11 percent and 15.42 percent respectively; the total flavone comprises flavonoids such as acacia substance, tilianin, linarin, agastachoside, isoagastachoside, agastachin, apigenin, apigenin-7- glucoside, 6-methoxyl group apigenin, luteolin and luteolin-7- glucoside, etc., wherein main flavone components are the agastachoside and the isoagastachoside , contents of which are 25.8 percent and 8.21 percent respectively; the triterpene materials comprises triterpene compounds such as cralaegolic acid, oleanolic acid, 3-acetyl oleanolic aldehvde, 3- acetyl oleanolic acid, alpha-amyrin, beta- amyrin, campesterol, campestanol, ursolic acid, erythrodiol, erythrodiol-3-acetic ester, wherein the main triterpene component is the cralaegolic acid , the content of which is 34.6 percent. The components have wide biological activities and a plurality of effects such as liver protection, anti-tumor, anti-HIV-1, anti-proteinase activity of HIV-1, anti-herpes zoster virus and immunity improvement, etc.

The present invention relates to a method of inhibiting HIV-1 activity in a cell. This method involves providing a cell infected with HIV-1 and contacting the cell with a compound of Formula I where R1 is —CH3, ═O, —OH, —OCH3, or —OC(O)CH3, and R2 is —H, —CH3, —CHO, —CH2OH, —CH2OCH3, —CH2OC(O)CH3, —COCH3, or —COOH, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell. A method of treating HIV-1 infection in a subject is also disclosed. This method involves administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

The present invention discloses an isoflavone compound shown as formula (I) contained in tobacco and a preparation method and application thereof. The method is as below: crushing a tobacco sample, conducting ultrasound extraction with 70% acetone 3 times, merging the extracts, filtering, conducting reduced pressure concentration on the filtrate to1 / 4-1 / 6 volume of the extract, standing, filtering the precipitate, and extracting with ethyl acetate ester three times to obtain an ethyl acetate extract liquid; and concentrating the extract into an extract, primarily separating the extract by silica gel column chromatography, then further separating the extract by high performance liquid preparative chromatography, so as to obtain the desired isoflavone compound. Antioxidant activity and anti-HIV-1 activity screening is conducted on the compound, and the experimental results show that the compound has strong antioxidant and anti-HIV-1 activity.

The invention discloses an application of triptolide in preparation of a medicament for treating or preventing human immunodeficiency viruses (HIV). The triptolide is diterpenoid naturally existing in roots of tripterygium wilfordii hook, and can dose-dependently inhibit replication of I type HIV (HIV-1) in cells in vitro. The half inhibitory concentrations on HIV-1 inhibition in TZM-b1 cells, JurkatT lymphocytes and human peripheral blood mononuclear cells are respectively 0.32nM, 0.45nM and 1.1nM. The triptolide has a remarkable inhibiting effect on the replication of the HIV-1 in the TZM-b1 cells, the JurkatT lymphocytes and the human peripheral blood mononuclear cells; and the triptolide is an active ingredient in Chinese medicinal tripterygium wilfordii hook, so the triptolide is wide in source. The compound has a broad prospect for developing anti-HIV-1 medicaments.

The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such formulations.

The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such formulations.

The invention belongs to the technical field of medicines, and particularly relates to a diarylpyrimidine derivative containing a biphenyl structure and a preparation method and application thereof. The compound structure disclosed by the invention relates to the diarylpyrimidine derivative containing the biphenyl structure shown as general formula I, and the invention further relates to a medicinal salt, a hydrate and a solvate thereof, a polycrystal or a co-crystal thereof, a precursor and a derivative with the same biological function thereof, a preparation method thereof and application ofa composition containing one or more of such compounds in related drugs for treating AIDS and the like. An in-vitro cell-level anti-HIV-1 activity experiment result shows that such small molecules have high anti-HIV-1 bioactivity, the replication of viruses in MT-4 cells infected by HIV-1 viruses can be notably inhibited, and moreover, cytotoxicity is low. (The general formula I is shown in the description.).

The invention discloses a screening method of an anti-HIV drug, which comprises the following steps: a sample to be tested is added to a fusion protein which expresses hA3G and reporter gene and a Vif cell; the blocking effect of the sample on Vif pathway is judged by investigating the quantity of the encoding products of the reporter gene; whether the initially chosen sample is an inhibitor in the pathway of proteasome degradation is further judged to screen out the anti-HIV drug. In the method provided by the invention, a hA3G is taken as a target point, solves the problem of drug resistance caused by high mutation of viruses and has no cross resistance with the anti-HIV-1 drug used in clinical application for the moment.

The invention discloses an HIV-1 multi-epitope recombinant protein, and an encoding gene and an application thereof. The protein provided by the invention is as follows: a) protein formed by amino acid sequences shown in the 13th to 164th bits of a sequence 1; b) protein formed by amino acid sequences shown in the sequence 1; or c) protein, which is obtained from the protein defined in a) or b) in a manner of replacing and / or missing and / or adding of one or more amino acid residues, and is related to anti-HIV-1. An experiment proves that the HIV-1 multi-epitope recombinant protein disclosed by the invention has good immunogenicity, and is an immunoreactive protein which has an application prospect and can be applied to prevention and treatment of HIV-1.

Disclosed is an applocation of an abstract of a plant endogenetic fungi fermentation product for antagonizing immunodeficiency virus(HIV). Said fungi is isolated from the roots of Orchidaceae medicinal herb Dendrobium nobile, and is EF1(Epulorhiza sp.); EF1s are fluid fermentation cultured to prepare an abstract of the fermentation product. The invention is provided with simplicity of fermentation art, short period of production, and mass industrialization production. The abstract of the fermentation product is obtained easily, and has a remarkable anti-HIV-1 activity, the acting site of which is after reverse transcription and before HIV RNA expression, with a regulation action of HIV-1 gene expression. An adding action is obtained by a combined use of the said fungi fermentation product and anti-HIV drug AZT, indicated by a drug combination test. The abstract of the fungi fermentation product has an important value in the development of novle anti-HIV drugs, and is hopefule to become a novel anti-HIV drug.

The invention discloses application of 1,8-dihexanoyl emodin in the preparation of anti-HIV-1 drugs and belongs to the field of antiviral drugs. It is discovered herein that 1,8-dihexanoyl emodin has in-vitro inhibitory action on HIV-1 virus replication, viral inclusions in infected human macrophages are decreased significantly, and no toxic and side effects are caused to human macrophages. The inhibitory action on HIV-1 replication increases with the increase in the concentration of the 1,8-dihexanoyl emodin in vitro, while Gag gene and p24 protein expressions decrease gradually; in addition, the longer the drugs act, the more significant the inhibitory action on HIV-1 infection. The 1,8-dihexanoyl emodin is applicable to the preparation of anti-HIV-1 drugs.

The invention discloses a dihydrochalcone-like compound (I) contained in tobacco and a preparation method and application thereof. The preparation method comprises the following steps: crushing a tobacco sample and then carrying out ultrasonic extraction by 70 percent of acetone for 3 times, merging extracting solutions, filtering and decompressing and concentrating the extracting solutions to a small volume, standing and then filtering deposits; extracting a filtrate by ethyl acetate for 3 times, and then obtaining partial extraction liquid of ethyl acetate; concentrating the extraction liquid into an extract, carrying out primary screen on the extract by silica gel column chromatography, and then adopting a high-efficiency liquid semipreparative chromatography for further separation, and then obtaining the required novel compound. Antioxidant activity and anti-HIV-1 activity screening is carried out on the compound, and an experimental result shows that the compound shows higher antioxidant activity and anti-HIV-1 activity.

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity.

The present invention is directed to peptides that are capable of blocking the entry of HIV-1 into host cells by means of the CCR5 receptor. The affinity of the peptides for gp120 on the HIV viral surface may be increased by sulfating tyrosine residues. In addition, the invention is directed to a method for increasing the affinity of antibodies for their antigens by sulfating tyrosine residues in the antibody amino acid chain.

The present invention relates, in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies and, in particular, to a formulation comprising a prehairpin intermediate form of HIV-1 envelope gp41 linked to a liposome. The invention also relates to methods of inducing broadly neutralizing anti-HIV-1 antibodies using such a formulation.

The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies. The invention therefore also relates to peptides containing the 4E10 epitope and to compositions made thereof, as well as to anti-idiotypic antibodies that are reactive with the paratope of 4E10-IgG1, to compositions containing an antiidiotypic antibody optionally in combination with a peptide containing the 4E10 epitope, and to anti-HIV-1 compositions comprising 4E10-IgG1, optionally in combination with another neutralizing antibody such as 2F5 and / or 2G12.